Try our beta test site

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: March 17, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted

Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.

Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.

The examination results will be given to the participants by a doctor from the neurology department.

Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment: 80
Study Start Date: March 2010
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

First degree relatives of diagnosed Parkinson patients that carry either LRRK2 or GBA gene mutation.

Ages: 30-80


Inclusion Criteria:

  • healthy first degree relatives of diagnosed Parkinson patients

Exclusion Criteria:

  • patients unable to understand and sign an informed consent
  • minors
  • people with psychiatric disorders or a history of major head trauma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01089270

Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Einat Even-Sapir, MD, PhD Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  More Information

Responsible Party: Einat Even-Sapir MD, PhD. Head, Dept of Nuclear Medicine, Tel Aviv Sourasky Medical Center Identifier: NCT01089270     History of Changes
Other Study ID Numbers: TASMC-10-EES-0519-CTIL 
Study First Received: March 17, 2010
Last Updated: March 17, 2010

Keywords provided by Tel-Aviv Sourasky Medical Center:
fdg pet-ct
i123 dat scan
first degree relatives of diagnosed Parkinson patients
with no clinical evidence of movement disorders

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on February 20, 2017